ETF Holdings Breakdown of XERS

Stock Name	Xeris Pharmaceuticals Inc
Ticker	XERS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US98422E1038

XERS institutional holdings

The following institutional investment holdings of XERS have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-15 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 99,379 2.1% USD 921,243 14.3%

2025-10-15 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 99,379 2.1% USD 921,243 14.3%

2025-10-15 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 104,095 USD 964,961

Total = 302,853 USD 2,807,447
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-15	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	99,379 2.1%	USD 921,243 14.3%
2025-10-15	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	99,379 2.1%	USD 921,243 14.3%
2025-10-15	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	104,095	USD 964,961
Total =	302,853	USD 2,807,447

News associated with XERS

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Significant Decline in Short Interest: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) saw a large decrease in short interest during the month of August. As of August 15th, there was short interest totaling 13,350,000 shares, adecreaseof26.7% from the July 31st total of 18,220,000 shares. Based on an average daily volume of 2,480,000 shares, the short-interest ratio is presently […] - 2025-09-09 02:57:07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.58 Average Price Target from Brokerages: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month […] - 2025-08-20 02:08:51
XERS Crosses Above Average Analyst Target: In recent trading, shares of Xeris Biopharma Holdings Inc (Symbol: XERS) have crossed above the average analyst 12-month target price of $6.30, changing hands for $6.60/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgr - 2025-08-08 08:32:33
Y Intercept Hong Kong Ltd Purchases Shares of 44,518 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Y Intercept Hong Kong Ltd purchased a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 44,518 shares of the company’s stock, valued at approximately $244,000. Several other large investors have also […] - 2025-07-31 05:00:49
Wealth Enhancement Advisory Services LLC Has $172,000 Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Wealth Enhancement Advisory Services LLC boosted its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 92.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,254 shares of the company’s stock after buying an additional 14,986 shares […] - 2025-07-10 04:20:58
Xeris Biopharma (NASDAQ:XERS) Trading 8.4% Higher Following Insider Buying Activity: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report)’s stock price was up 8.4% on Tuesday following insider buying activity. The company traded as high as $4.70 and last traded at $4.77. Approximately 437,729 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 1,978,886 shares. The stock had […] - 2025-06-19 02:13:05
Two Sigma Advisers LP Acquires Shares of 13,741 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Two Sigma Advisers LP acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund acquired 13,741 shares of the company’s stock, valued at approximately $47,000. Other hedge funds and other institutional investors have also recently made changes to their positions in the company. […] - 2025-06-09 04:26:55
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Wellington Management Group LLP: Wellington Management Group LLP lowered its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 1.4% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 465,112 shares of the company’s stock after selling 6,532 shares during the period. Wellington Management Group LLP’s holdings in Xeris Biopharma were worth $1,577,000 at […] - 2025-06-06 05:38:55
Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Price Target at $6.25: Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) have been given an average rating of “Moderate Buy” by the six ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average […] - 2025-06-06 02:05:00
Mackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Mackenzie Financial Corp raised its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 446.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 129,952 shares of the company’s stock after acquiring an additional 106,153 shares during the quarter. Mackenzie Financial […] - 2025-06-04 05:19:00
Xeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to Hold: Wall Street Zen downgraded shares of Xeris Biopharma (NASDAQ:XERS – Free Report) from a buy rating to a hold rating in a research note published on Thursday morning. A number of other research firms also recently weighed in on XERS. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave […] - 2025-05-23 05:10:55
Northern Trust Corp Acquires 38,155 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Northern Trust Corp raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 3.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,196,381 shares of the company’s stock after purchasing an additional 38,155 shares during the period. Northern Trust Corp’s holdings in […] - 2025-05-23 04:16:53
Price T Rowe Associates Inc. MD Has $578,000 Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Price T Rowe Associates Inc. MD lifted its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 5.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 170,482 shares of the company’s stock after purchasing an additional 9,506 shares during the quarter. Price […] - 2025-05-13 04:32:46
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $6.10 Average Target Price from Analysts: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price […] - 2025-05-12 02:56:42
Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $7.00: Xeris Biopharma (NASDAQ:XERS – Free Report) had its target price raised by Oppenheimer from $6.00 to $7.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other research analysts have also commented on XERS. Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to […] - 2025-05-12 02:22:42
Legal & General Group Plc Has $781,000 Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Legal & General Group Plc lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 9.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 230,467 shares of the company’s stock after acquiring an additional 19,624 shares during the period. Legal & General Group Plc’s holdings in Xeris […] - 2025-04-28 04:45:02
Virtu Financial LLC Makes New $58,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Virtu Financial LLC acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,137 shares of the company’s stock, valued at approximately $58,000. A number of other hedge funds have also made […] - 2025-04-01 04:57:01
Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High – Still a Buy?: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $3.89 and last traded at $3.88, with a volume of 2500599 shares trading hands. The stock had previously closed at $3.59. Wall Street Analysts Forecast Growth A number of research […] - 2025-02-19 04:51:36
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by China Universal Asset Management Co. Ltd.: China Universal Asset Management Co. Ltd. grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 10.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,611 shares of the company’s stock after acquiring an additional 2,954 shares during […] - 2025-02-04 07:15:12
R Squared Ltd Makes New $42,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): R Squared Ltd purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 12,320 shares of the company’s stock, valued at approximately $42,000. Other hedge funds and other institutional investors have also recently made changes to their positions in the […] - 2025-02-03 06:49:07

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.